2-溴-4,5,6,7-四氢-1-苯并噻吩 | 111873-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-溴-4,5,6,7-四氢-1-苯并噻吩
• 英文名称: 2-bromo-4,5,6,7-tetrahydrobenzo[b]thiophene
• 英文别名: 2-bromo-4,5,6,7-tetrahydro-1-benzothiophene
• CAS: 111873-07-5
• 化学式: C₈H₉BrS
• 分子量: 217.129
• InChiKey: CJRRLCPMBQMCRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-溴-4,5,6,7-四氢-1-苯并噻吩 在 溴乙烷 、 乙醚 、 magnesium 作用下， 生成 4,5,6,7-四氢苯并[B]噻吩二甲酸
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1955, p. 1252,1255

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5,6,7-四氢-1-苯并噻吩 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-溴-4,5,6,7-四氢-1-苯并噻吩
  参考文献：
  名称：

  [EN] ARYLAMIDES AND METHODS OF USE THEREOF
  [FR] ARYLAMIDES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及杂环化合物，其药用盐以及药物制剂。本文还描述了这些化合物的组成以及在治疗由CFTR活性不足介导的疾病和病况的方法中的使用，特别是囊性纤维化。

  公开号：

  WO2021113809A1

文献信息

• [EN] ARYLAMIDES AND METHODS OF USE THEREOF<br/>[FR] ARYLAMIDES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENZYME CORP

  公开号：WO2021113809A1

  公开（公告）日：2021-06-10

  The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

  本公开涉及杂环化合物，其药用盐以及药物制剂。本文还描述了这些化合物的组成以及在治疗由CFTR活性不足介导的疾病和病况的方法中的使用，特别是囊性纤维化。
• [EN] COMPOUNDS FOR USE AS GPR120 AGONISTS<br/>[FR] COMPOSÉS POUVANT ÊTRE UTILISÉS À TITRE D'AGONISTES DE GPR120
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015125085A1

  公开（公告）日：2015-08-27

  The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of a compound of formula (I) for the treatment of metabolic disorders, particularly Type 2 diabetes and associated diseases.

  本发明涉及一种式（I）的化合物，或其互变异构体、立体异构体、几何异构体、前药、羧酸同工体、溶剂合物、多形体、N-氧化物、S-氧化物或其药学上可接受的盐，它们是GPR120激动剂。本发明还涉及一种式（I）的化合物的药物组合物，用于治疗代谢紊乱，特别是2型糖尿病及相关疾病。
• Synthesis, characterization, and electrogenerated chemiluminescence of phenyl-substituted, phenyl-annulated, and spirofluorenyl-bridged oligothiophenes
  作者：Ullrich Mitschke、Peter Bäuerle

  DOI：10.1039/b006553f

  日期：——

  To overcome the insolubility of higher oligothiophenes and simultaneously to enhance their processability with respect to an application in molecularly doped organic light-emitting devices (OLEDs) we synthesized phenyl-substituted, phenyl-annulated, and spirofluorenyl-bridged oligothiophenes 1–5. Significantly improved solubilities in polar solvents of up to three orders of magnitude were found and their optical and electrochemical properties were investigated in solution. Reflecting small conformational changes and the almost complete electronic separation of the substituents, phenyl substitution and the introduction of a spiro core by bridging the central bithienyl unit only slightly affected optical and redox properties in comparison to the unmodified oligothiophenes (6–8). In contrast, the presence of an isothianaphthene (benzo[c]thiophene) unit in the oligomeric chain led to a distinct approximation of the frontier orbitals and consequently to a red-shift of both absorption and fluorescence. Finally, we demonstrated the applicability of some oligomers as dopants for OLEDs by electrogenerated chemiluminescence (ECL).

  为了克服高阶寡聚噻吩的不溶性并同时提高它们在分子掺杂有机发光二极管(OLEDs)应用中的可加工性,我们合成了苯基取代的、苯基稠合的和螺芴基桥连的寡聚噻吩1-5。研究发现这些化合物在极性溶剂中的溶解度显著提高了最多三个数量级,并对它们在溶液中的光学和电化学性质进行了研究。与未修饰的寡聚噻吩(6-8)相比,苯基取代和通过桥连中心联噻吩基团引入螺环核心仅略微影响了光学和氧化还原性质,这反映了构象的微小变化和取代基之间几乎完全的电子分离。相比之下,寡聚物链中异噻萘(苯并[c]噻吩)单元的存在导致前沿轨道的明显趋近,因此吸收和荧光都发生红移。最后,我们通过电化学发光(ECL)证明了某些寡聚物作为OLED掺杂剂的适用性。
• Synthesis and One-Electron Oxidation Chemistry of Stable β,β-Dimesityl Enols with Heteroaryl Substituents
  作者：Michael Schmittel、Mukul Lal、Wolfdieter A. Schenk、Michael Hagel、Nicolai Burzlaff、Anja Langels

  DOI：10.1515/znb-2003-0910

  日期：2003.9.1

  Four novel stable enols (one characterized by X-ray crystal structure analysis) were synthesized and investigated under oxidative conditions to yield benzofurans. Depending on the donor qualities of the heteroaryl substituent the reaction following the one-electron oxidation could be stopped on the stage of the cyclohexadienyl cation whose lifetime was measured. Oxidation potentials were determined for the enols, the enolates and the α-carbonyl radicals. Oxidation of benzofurans yielded dimeric species or intramolecular cyclization products.

  合成了四种新型稳定烯醇（其中一种通过X射线晶体结构分析进行了表征），并在氧化条件下进行研究，得到了苯并呋喃类化合物。根据杂环芳基取代基的给体性质，一电子氧化后的反应可以在环己二烯基阳离子阶段停止，其寿命得到了测量。对烯醇、烯醇负离子和α-羰基自由基进行了氧化电位的测定。苯并呋喃的氧化产物为二聚体物种或分子内环化产物。
• DIAZACARBAZOLES AND METHODS OF USE
  申请人：Chen Huifen

  公开号：US20110118230A1

  公开（公告）日：2011-05-19

  The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及式（I），（I-a）和（I-b）的1,7-二氮杂咔唑化合物，其作为激酶抑制剂有用，更具体地作为检查点激酶1（chk1）抑制剂有用，因此可用作癌症治疗剂。本发明还涉及包含这些化合物的组合物，更具体地是药物组合物，并使用它们治疗各种形式的癌症和增生性疾病的方法，以及使用这些化合物进行哺乳动物细胞的体外、原位和体内诊断或治疗的方法，或相关的病理条件。